BillionaireClubCollc
  • News
  • Notifications
  • Shop
  • Cart
  • Media
  • Advertise with Us
  • Profile
  • Groups
  • Games
  • My Story
  • Chat
  • Contact Us
home shop notifications more
Signin
  •  Profile
  •  Sign Out
Skip to content

Billionaire Club Co LLC

Believe It and You Will Achieve It

Primary Menu
  • Home
  • Politics
  • TSR
  • Anime
  • Michael Jordan vs.Lebron James
  • Crypto
  • Soccer
  • Dating
  • Airplanes
  • Forex
  • Tax
  • New Movies Coming Soon
  • Games
  • CRYPTO INSURANCE
  • Sport
  • MEMES
  • K-POP
  • AI
  • The Bahamas
  • Digital NoMad
  • Joke of the Day
  • RapVerse
  • Stocks
  • SPORTS BETTING
  • Glamour
  • Beauty
  • Travel
  • Celebrity Net Worth
  • TMZ
  • Lotto
  • COVD-19
  • Fitness
  • The Bible is REAL
  • OutDoor Activity
  • Lifestyle
  • Culture
  • Boxing
  • Food
  • LGBTQ
  • Poetry
  • Music
  • Misc
  • Open Source
  • NASA
  • Science
  • Natural & Holstict Med
  • Gardening
  • DYI
  • History
  • Art
  • Education
  • Pets
  • Aliens
  • Astrology
  • Farming and LiveStock
  • LAW
  • Fast & Furious
  • Fishing & Hunting
  • Health
  • Credit Repair
  • Grants
  • All things legal
  • Reality TV
  • Africa Today
  • China Today
  • "DUMB SHIT.."
  • Stocks

Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug

Hero Images / Getty Images

Key TakeawaysBiohaven said its experimental treatment for a rare neurological condition showed "a robust and clinically meaningful" slowing of the disease.The study of the drug troriluzole found a 50% to 70% slower rate of decline over three years for patients with spinocerebellar ataxia (SCA).The news sent Biohaven shares soaring 15% and moving into positive territory for the year.
Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.The company reported data collected over multiple analyses of its drug, troriluzole, showed "a robust and clinically meaningful slowing of disease progression" over a three-year period in patients with spinocerebellar ataxia, or SCA.Biohaven noted that SCA is a progressively debilitating neurodegenerative disease that affects some 15,000 people in the U.S. and 24,000 in Europe and the U.K., and there is no Food and Drug Administration (FDA)-approved medicine for it.Those Taking Drug Had 50% to 70% Slower Rate of DeclineThe research indicated those taking troriluzole had a 50% to 70% slower rate of decline compared with untreated patients, which it explained represented a delay in disease progression of 1.5 years to 2.2 years over the three-year study period.Biohaven said that it plans to submit a New Drug Application to the FDA in the fourth quarter of this year, and with approval expects to have troriluzole on the market in the U.S. next year.The news sent shares of Biohaven into positive territory for 2024.

TradingView

Read the original article on Investopedia.

Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!

Source link

Share
What's your thought on the article, write a comment
0 Comments
×

Sign In to perform this Activity

Sign in
×

Account Frozen

Your account is frozen. You can still view content but cannot interact with it.

Please go to your settings to update your account status.

Open Profile Settings

Ads

  • Premium Billionaire128 Women’s Racerback Tank

    $ 24.50
  • Premium Billionaire128 Women’s Crop Tee

    $ 22.50
  • Original Billionaire128 Fanny Pack

    $ 35.00
  • News Social

    • Facebook
    • Twitter
    • Facebook
    • Twitter
    Copyright © 2024 Billionaire Club Co LLC. All rights reserved